Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (16)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  2. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 35, Núm. 7, pp. 630-642

  3. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 2060-2069

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

2019

  1. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2018

  1. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826

  2. Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  3. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)

    Clinical and Translational Oncology

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2009

  1. Prognostic and predictive factors and genetic analysis of early breast cancer

    Clinical and Translational Oncology

2006

  1. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation

    International Journal of Radiation Oncology Biology Physics, Vol. 64, Núm. 4, pp. 1122-1128

2005

  1. Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 61, Núm. 5, pp. 1378-1384

2002

  1. Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer

    British Journal of Cancer, Vol. 87, Núm. 2, pp. 158-160